AbbVie may count on Allergan's Botox for post-merger growth. But what else?

With a $63 billion merger nearing approval, AbbVie is looking to Allergan for a boost in the new company's drug portfolio. In the case of Botox, AbbVie might have a long-term winner, but not every drug in Allergan's stable is shining quite so brightly.